Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 34


Extracellular signal regulated kinase 5 and inflammasome in progression of mesothelioma.

Thompson JK, Shukla A, Leggett AL, Munson PB, Miller JM, MacPherson MB, Beuschel SL, Pass HI, Shukla A.

Oncotarget. 2017 Dec 6;9(1):293-305. doi: 10.18632/oncotarget.22968. eCollection 2018 Jan 2.


Asbestos-Induced Mesothelial to Fibroblastic Transition Is Modulated by the Inflammasome.

Thompson JK, MacPherson MB, Beuschel SL, Shukla A.

Am J Pathol. 2017 Mar;187(3):665-678. doi: 10.1016/j.ajpath.2016.11.008. Epub 2017 Jan 3.


Exploratory use of docetaxel loaded acid-prepared mesoporous spheres for the treatment of malignant melanoma.

Kaiser S, MacPherson MB, James TA, Emery A, Spiess P, van der Vliet A, Landry CC, Shukla A.

Cancer Nanotechnol. 2015;6:1. Epub 2015 Jan 24.


Antitumor effects of TRAIL-expressing mesenchymal stromal cells in a mouse xenograft model of human mesothelioma.

Lathrop MJ, Sage EK, Macura SL, Brooks EM, Cruz F, Bonenfant NR, Sokocevic D, MacPherson MB, Beuschel SL, Dunaway CW, Shukla A, Janes SM, Steele C, Mossman BT, Weiss DJ.

Cancer Gene Ther. 2015 Jan;22(1):44-54. doi: 10.1038/cgt.2014.68. Epub 2014 Dec 19.


CREB-induced inflammation is important for malignant mesothelioma growth.

Westbom CM, Shukla A, MacPherson MB, Yasewicz EC, Miller JM, Beuschel SL, Steele C, Pass HI, Vacek PM, Shukla A.

Am J Pathol. 2014 Oct;184(10):2816-27. doi: 10.1016/j.ajpath.2014.06.008. Epub 2014 Aug 8.


Extracellular signal-regulated kinase 5 and cyclic AMP response element binding protein are novel pathways inhibited by vandetanib (ZD6474) and doxorubicin in mesotheliomas.

Sayan M, Shukla A, MacPherson MB, Macura SL, Hillegass JM, Perkins TN, Thompson JK, Beuschel SL, Miller JM, Mossman BT.

Am J Respir Cell Mol Biol. 2014 Nov;51(5):595-603. doi: 10.1165/rcmb.2013-0373TR.


Asbestos modulates thioredoxin-thioredoxin interacting protein interaction to regulate inflammasome activation.

Thompson JK, Westbom CM, MacPherson MB, Mossman BT, Heintz NH, Spiess P, Shukla A.

Part Fibre Toxicol. 2014 May 20;11:24. doi: 10.1186/1743-8977-11-24.


Curcumin: a double hit on malignant mesothelioma.

Miller JM, Thompson JK, MacPherson MB, Beuschel SL, Westbom CM, Sayan M, Shukla A.

Cancer Prev Res (Phila). 2014 Mar;7(3):330-40. doi: 10.1158/1940-6207.CAPR-13-0259. Epub 2014 Jan 15.


Microspheres targeted with a mesothelin antibody and loaded with doxorubicin reduce tumor volume of human mesotheliomas in xenografts.

Macura SL, Steinbacher JL, Macpherson MB, Lathrop MJ, Sayan M, Hillegass JM, Beuschel SL, Perkins TN, Spiess PC, van der Vliet A, Butnor KJ, Shukla A, Wadsworth M, Landry CC, Mossman BT.

BMC Cancer. 2013 Sep 11;13:400. doi: 10.1186/1471-2407-13-400.


Asbestos and erionite prime and activate the NLRP3 inflammasome that stimulates autocrine cytokine release in human mesothelial cells.

Hillegass JM, Miller JM, MacPherson MB, Westbom CM, Sayan M, Thompson JK, Macura SL, Perkins TN, Beuschel SL, Alexeeva V, Pass HI, Steele C, Mossman BT, Shukla A.

Part Fibre Toxicol. 2013 Aug 13;10:39. doi: 10.1186/1743-8977-10-39.


Extracellular signal-regulated kinase 5: a potential therapeutic target for malignant mesotheliomas.

Shukla A, Miller JM, Cason C, Sayan M, MacPherson MB, Beuschel SL, Hillegass J, Vacek PM, Pass HI, Mossman BT.

Clin Cancer Res. 2013 Apr 15;19(8):2071-83. doi: 10.1158/1078-0432.CCR-12-3202. Epub 2013 Feb 27.


A multifunctional mesothelin antibody-tagged microparticle targets human mesotheliomas.

Macura SL, Hillegass JM, Steinbacher JL, MacPherson MB, Shukla A, Beuschel SL, Perkins TN, Butnor KJ, Lathrop MJ, Sayan M, Hekmatyar K, Taatjes DJ, Kauppinen RA, Landry CC, Mossman BT.

J Histochem Cytochem. 2012 Sep;60(9):658-74. doi: 10.1369/0022155412452567. Epub 2012 Jun 21.


ERK2 is essential for the growth of human epithelioid malignant mesotheliomas.

Shukla A, Hillegass JM, MacPherson MB, Beuschel SL, Vacek PM, Butnor KJ, Pass HI, Carbone M, Testa JR, Heintz NH, Mossman BT.

Int J Cancer. 2011 Sep 1;129(5):1075-86. doi: 10.1002/ijc.25763. Epub 2011 Jan 6.


Osteopontin modulates inflammation, mucin production, and gene expression signatures after inhalation of asbestos in a murine model of fibrosis.

Sabo-Attwood T, Ramos-Nino ME, Eugenia-Ariza M, Macpherson MB, Butnor KJ, Vacek PC, McGee SP, Clark JC, Steele C, Mossman BT.

Am J Pathol. 2011 May;178(5):1975-85. doi: 10.1016/j.ajpath.2011.01.048.


An extracellular signal-regulated kinase 2 survival pathway mediates resistance of human mesothelioma cells to asbestos-induced injury.

Shukla A, Barrett TF, MacPherson MB, Hillegass JM, Fukagawa NK, Swain WA, O'Byrne KJ, Testa JR, Pass HI, Faux SP, Mossman BT.

Am J Respir Cell Mol Biol. 2011 Nov;45(5):906-14. doi: 10.1165/rcmb.2010-0282OC. Epub 2011 Mar 31.


Blocking of ERK1 and ERK2 sensitizes human mesothelioma cells to doxorubicin.

Shukla A, Hillegass JM, MacPherson MB, Beuschel SL, Vacek PM, Pass HI, Carbone M, Testa JR, Mossman BT.

Mol Cancer. 2010 Dec 15;9:314. doi: 10.1186/1476-4598-9-314.


Mechanisms of oxidative stress and alterations in gene expression by Libby six-mix in human mesothelial cells.

Hillegass JM, Shukla A, MacPherson MB, Lathrop SA, Alexeeva V, Perkins TN, van der Vliet A, Vacek PM, Gunter ME, Mossman BT.

Part Fibre Toxicol. 2010 Sep 11;7:26. doi: 10.1186/1743-8977-7-26.


Increased efficacy of doxorubicin delivered in multifunctional microparticles for mesothelioma therapy.

Hillegass JM, Blumen SR, Cheng K, MacPherson MB, Alexeeva V, Lathrop SA, Beuschel SL, Steinbacher JL, Butnor KJ, Ramos-NiƱo ME, Shukla A, James TA, Weiss DJ, Taatjes DJ, Pass HI, Carbone M, Landry CC, Mossman BT.

Int J Cancer. 2011 Jul 1;129(1):233-44. doi: 10.1002/ijc.25666. Epub 2010 Nov 3.


Inflammation precedes the development of human malignant mesotheliomas in a SCID mouse xenograft model.

Hillegass JM, Shukla A, Lathrop SA, MacPherson MB, Beuschel SL, Butnor KJ, Testa JR, Pass HI, Carbone M, Steele C, Mossman BT.

Ann N Y Acad Sci. 2010 Aug;1203:7-14. doi: 10.1111/j.1749-6632.2010.05554.x.


Enhanced uptake of porous silica microparticles by bifunctional surface modification with a targeting antibody and a biocompatible polymer.

Cheng K, Blumen SR, MacPherson MB, Steinbacher JL, Mossman BT, Landry CC.

ACS Appl Mater Interfaces. 2010 Sep;2(9):2489-95. doi: 10.1021/am100530t.

Supplemental Content

Loading ...
Support Center